The green light comes on the back of the phase 3 ARCHWAY trial which showed that Susvimo was equivalent to monthly Lucentis injections at maintaining vision in patients over 40 weeks, with 98% of ...

he was one of five chosen for a clinical trial of Lucentis, a new drug just approved by the FDA to treat the wet form of the disease. Each month for 2 years Verle received an injection directly ...

Patients with diabetic macular edema previously treated with a ranibizumab biosimilar in India experience comparable safety ...

Assistant U.S. Attorney Roger Stefin claimed some of Melgen's patients developed serious eye infections from unnecessary Lucentis injections administered on the basis of bogus macular degeneration ...

In addition to comparable BCVA levels, the researchers concluded that the PDS implant “provides effective, durable, and generally well-tolerated treatment for DME with retreatment every 6 months ...

In this study, 4300 patients received 0.3 or 0.5 mg of ranibizumab every 3 months after the initial series of three monthly injections. After the first 3 injections the mean visual acuity improved ...